How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas

NCT04908267 | Unknown

• 1 other identifier: 2022198
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence. Habitat imaging is a segmentation technique by dividing tumor regions to characterize tumor heterogeneity based on tumor pathology, blood perfusion, molecular characteristics and other tumor biological features. In some studies, the Hemodynamic Multiparametric Tissue Signature (HTS) method has been proven to be feasible. The Hemodynamic Multiparametric Tissue Signature (HTS) consists of a set of vascular habitats obtained by Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI) of high-grade gliomas using a multiparametric unsupervised analysis method. This allowed them to automatically draw 4 reproducible vascular habitats (High-angiogenic enhancing tumor; Low-angiogenic enhancing tumor; Potentially tumor infiltrated peripheral edema; Vasogenic peripheral edema) which enable to describe the tumor vascular heterogeneity robustly. In other studies, contrast-enhancing mass can divided into spatial habitats by K-means clustering of voxel-wise apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) values to observe the changes of voxels in spatial habitat on the time line. Using this so-called spatiotemporal habitat to identify progression or pseudoprogression in cancer therapy. Above all, we have sufficient and firm reasons to deem that habitat imaging based on multiparametric MRI is more conducive to reflect the potential biological information inside the tumor and realize individualized diagnosis and treatment. To sum up, the assumption of this experiment is that the Habitats Created by preoperative or postoperative Multiparametric MRI ,such as conventional MRI sequences, Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI), Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted Magnetic Resonance Imaging(DWI) ,Vessel Size Imaging (VSI) ,or Magnetic Resonance Spectroscopy (MRS) can predict the molecular mutation status, prognosis, treatment residence, progression, pseudoprogression, and even recurrence and distant intracranial recurrence in patients with high-grade gliomas.

Conditions

High-grade Glioma

Keywords

habitat imaging; high-grade glioma; radiomics; heterogeneity; recurrence

Outcome Measures

Primary Outcomes (1)

• Multi-model habitats constructed by multiparametric MRI predict IDH mutation status and the prognosis in high-grade gliomas

  The IDH status of each patient was dependent on pathological and immunohistochemical results. The overall survival for each patient is estimated since the date of operation to the end of recruitment. The overall survival will be confirmed through clinical follow-up.

  From the date of operation until the date of death from any cause，assessed up to 120 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The subjects we selected are adults who are not restricted by gender. For details, please refer to the "criteria" column.

You may qualify if:

• the patient was over 18 years old
• the lesion was located in the supratentorial space;
• a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
• all subjects were the first diagnosed cases without any invasive or non-invasive treatment;
• access to the complete preoperative MR imaging examinations, at least including four conventional sequences.
• the patient was over 18 years old;
• the lesion was located in the supratentorial space;
• a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
• underwent concurrent chemoradiotherapy with temozolomide after surgical resection or biopsy;
• underwent preoperative and postoperative MRI, at least including four conventional sequences;
• had newly appeared or enlarging, measurable, contrast-enhancing mass which raises clinical suspicion of tumor recurrence and distant intracranial recurrence;
• adequate follow-up examinations to determine treatment response on clinic-radiological consensus or pathologic confirmation.

You may not qualify if:

• patient with other brain tumors or other grade gliomas at the same time;
• patient with severe basic diseases at the same time;
• patient with a survival time of less than 30 days, which can be caused by severe surgical trauma stress;
• poor image quality and heavy artifact affect the subsequent image processing.

Sponsors & Collaborators

• Weiguo Zhang: lead

Study Sites (1)

Department of Radiology, Daping Hospital of Army Medical University

Chongqing, Chongqing Municipality, 400042, China

RECRUITING

Related Publications (1)

• Wu H, Tong H, Du X, Guo H, Ma Q, Zhang Y, Zhou X, Liu H, Wang S, Fang J, Zhang W. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas. Eur Radiol. 2020 Jun;30(6):3254-3265. doi: 10.1007/s00330-020-06702-2. Epub 2020 Feb 20.

  PMID: 32078014 BACKGROUND

Related Links

• Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas

MeSH Terms

Conditions

Glioma; Recurrence

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Weiguo Zhang, Ph.D

  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jiachen Liu, M.D.

CONTACT

(+86)18434161824; JCliu0430@163.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director of Radiology Department

Study Record Dates

• First Submitted: May 17, 2021
• First Posted: June 1, 2021
• Study Start: August 1, 2022
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: January 11, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)